ARUP Laboratories
500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Julio C. Delgado, M.D. M.S., Director of Laboratories

*****Example Report*****

Patient Age/Gender: Unknown Unknown
Printed: 08-Jun-20 13:39:34

Procedure	Result		Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
Benzoylecgonine, S/P, Quant	55		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Amphetamines, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Methamphetamine, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Barbiturates, S/P, Screen	Positive	f	ng/mL	[Cutoff 50]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Benzodiazepines, S/P, Screen	Positive	f	ng/mL	[Cutoff 50]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Buprenorphine, S/P, Screen	Positive	f	ng/mL	[Cutoff 1]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Cannabinoids, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Cocaine, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Methadone, S/P, Screen	Positive	f	ng/mL	[Cutoff 25]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Opiates, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Oxycodone, S/P, Screen	Positive	f	ng/mL	[Cutoff 20]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Phencyclidine, S/P, Screen	Positive	f	ng/mL	[Cutoff 10]	20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Drug Screen Comments, Serum or Plasma	See Note				20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
11-Nor-9-carboxy-THC, S/P, Quant	16		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Buprenorphine, S/P, Quant	2.0		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Norbuprenorphine, S/P, Quant	2.0		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Methadone, S/P, Quant	11		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
EDDP, S/P, Quant	11		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
6-acetylmorphine, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Codeine, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Morphine, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Hydrocodone, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Hydromorphone, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Oxycodone, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Oxymorphone, S/P, Quant	3	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Amphetamine, S/P, Quant	21	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Methamphetamine, S/P, Quant	21	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
MDA, S/P, Quant	21	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
MDMA, S/P, Quant	21	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
MDEA, S/P, Quant	21	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Phencyclidine (PCP), S/P, Quant	11		ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Diazepam, S/P, Quant	20	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Nordiazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Oxazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Temazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Chlordiazepoxide, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Lorazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Alprazolam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Alpha-hydroxyalprazolam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Clonazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
7-aminoclonazepam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Midazolam, S/P, Quant	25	f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12

***** Abnormal, **#** = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, **@** = Reference Lab

Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
Butalbital, S/P, Quant	51	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Phenobarbital, S/P, Quant	51	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Alpha-hydroxymidazolam, S/P, Quant	25 f	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Pentobarbital, S/P, Quant	51	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Secobarbital, S/P, Quant	51	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12
Amobarbital, S/P, Quant	51	ng/mL		20-160-900081	08-Jun-20 11:40:00	08-Jun-20 11:40:00	08-Jun-20 13:34:12

08-Jun-20 11:40:00 Amphetamines, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Methamphetamine, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Barbiturates, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Benzodiazepines, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Buprenorphine, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Cannabinoids, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Cocaine, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Methadone, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Opiates, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Oxycodone, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply.
Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 Phencyclidine, S/P, Screen:

If the screen is positive, then confirmation by mass spectrometry will be added. Additional charges will apply. Unconfirmed positive may be useful for medical purposes, but does not meet forensic standards.

08-Jun-20 11:40:00 6-acetylmorphine, S/P, Quant:

6-Acetylmorphine (6-AM) indicates use of heroin. 6-AM is metabolized to morphine.

08-Jun-20 11:40:00 Codeine, S/P, Quant:

Codeine is not a recognized metabolite of other opiates and its presence usually indicates use of a codeine-containing drug. Codeine is metabolized to morphine and hydrocodone.

08-Jun-20 11:40:00 Morphine, S/P, Quant:

Morphine may arise from morphine-containing drugs, poppy seeds, or by metabolism of either codeine or 6-AM. Morphine is metabolized to hydromorphone.

08-Jun-20 11:40:00 Hydrocodone, S/P, Quant:

Hydrocodone may arise from hydrocodone-containing drugs or as a metabolite of codeine. Hydrocodone is metabolized to hydromorphone.

08-Jun-20 11:40:00 Hydromorphone, S/P, Quant:

Hydromorphone may arise from hydromorphone-containing drugs or by metabolism of either morphine or hydrocodone.

08-Jun-20 11:40:00 Oxycodone, S/P, Quant:

Oxycodone is not a recognized metabolite of other opiates and its presence indicates use of an oxycodone-containing drug. Oxycodone is metabolized to oxymorphone.

08-Jun-20 11:40:00 Oxymorphone, S/P, Quant:

Oxymorphone may arise from oxymorphone-containing drugs or by metabolism of oxycodone.

08-Jun-20 11:40:00 Amphetamine, S/P, Quant:

Consistent with use of a drug containing amphetamine. May also reflect metabolism of methamphetamine, when methamphetamine is present. Amphetamine and methamphetamine exist in d- and l-isomeric forms. These forms are not distinguished by this test. Isomeric separation is available separately for an additional charge.

08-Jun-20 11:40:00 Methamphetamine, S/P, Quant:

Consistent with use of a drug containing methamphetamine. Methamphetamine is metabolized to amphetamine. Amphetamine and methamphetamine exist in d- and l-isomeric forms. These forms are not distinguished by this test. Isomeric separation is available separately for an additional charge.

08-Jun-20 11:40:00 MDA, S/P, Quant:

Consistent with use of an illicit drug containing 3,4-methylenedioxyamphetamine (MDA). May also reflect metabolism of MDMA or MDEA.

08-Jun-20 11:40:00 MDMA, S/P, Quant:

Consistent with use of an illicit drug containing 3,4-methylenedioxy-N-methylamphetamine (MDMA). MDMA is metabolized to MDA.

08-Jun-20 11:40:00 MDEA, S/P, Quant:

Consistent with use of an illicit drug containing 3,4-methylenedioxy-N-ethylamphetamine (MDEA). MDEA is metabolized to MDA.

08-Jun-20 11:40:00 Diazepam, S/P, Quant:

Consistent with use of a drug containing diazepam, such as Valium; metabolites include nordiazepam, temazepam, and oxazepam.

08-Jun-20 11:40:00 Nordiazepam, S/P, Quant:

Metabolite of several benzodiazepines, such as chlordiazepoxide (Librium), prazepam (Centrax), halezepam (Alapryl), clorazepate (Tranxene), and others.

08-Jun-20 11:40:00 Oxazepam, S/P, Quant:

Consistent with use of a drug containing oxazepam, such as Serax, or use of a drug that is metabolized to oxazepam.

08-Jun-20 11:40:00 Temazepam, S/P, Quant:

Consistent with use of a drug containing temazepam, such as Restoril, or use of a drug that is metabolized to temazepam.

08-Jun-20 11:40:00 Chlordiazepoxide, S/P, Quant:

Consistent with use of a drug containing chlordiazepoxide, such as Librium.

08-Jun-20 11:40:00 Lorazepam, S/P, Quant:

Consistent with use of a drug containing lorazepam, such as Ativan.

08-Jun-20 11:40:00 Alprazolam, S/P, Quant:

Consistent with use of a drug containing alprazolam, such as Xanax.

08-Jun-20 11:40:00 Alpha-hydroxyalprazolam, S/P, Quant:

Alprazolam metabolite; consistent with use of a drug containing alprazolam, such as Xanax.

08-Jun-20 11:40:00 Clonazepam, S/P, Quant:

Consistent with use of a drug containing clonazepam, such as Klonopin.

08-Jun-20 11:40:00 7-aminoclonazepam, S/P, Quant:

Clonazepam metabolite; consistent with use of a drug containing clonazepam, such as Klonopin.

08-Jun-20 11:40:00 Midazolam, S/P, Quant:

Consistent with use of a drug containing midazolam, such as Versed.

08-Jun-20 11:40:00 Alpha-hydroxymidazolam, S/P, Quant:

Consistent with use of a drug containing midazolam, such as Versed.

08-Jun-20 11:40:00 Benzoylecgonine, S/P, Quant:
INTERPRETIVE INFORMATION: Cocaine Metabolite,
Serum or Plasma,
Quantitative

Methodology: Quantitative Gas Chromatography- Mass Spectrometry

Positive cutoff: 20 ng/mL

For medical purposes only; not valid for forensic use.

The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Drug Screen Comments, Serum or Plasma:
INTERPRETIVE INFORMATION: Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation

1. Methodology: Qualitative Immunoassay Screen

2. Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation testing. An immunoassay unconfirmed positive screen result may be useful for medical purposes but does not meet forensic standards.

3. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (mass spectrometry). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

4. For medical purposes only; not valid for forensic use.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 11-Nor-9-carboxy-THC, S/P, Quant:
INTERPRETIVE INFORMATION: THC Metabolite, Serum or Plasma, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry.

Positive cutoff: 5 ng/mL

For medical purposes only; not valid for forensic use.

The drug analyte detected in this assay, 9-carboxy THC, is a metabolite of delta-9-tetrahydrocannabinol (THC). Detection of 9-carboxy THC suggests use of, or exposure to, a product containing THC. This test cannot distinguish between prescribed or non-prescribed forms of THC, nor can it distinguish between active or passive use. The plasma half-life for 9-carboxy THC metabolite is estimated to range from 4-12 hours.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Buprenorphine, S/P, Quant:
INTERPRETIVE INFORMATION: Buprenorphine and Metabolites,
Serum or Plasma, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 1 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is common and may indicate use of parent drug during the prior week. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Methadone, S/P, Quant:
INTERPRETIVE INFORMATION: Methadone and Metabolite,
Serum or Plasma,
Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 10 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the
cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 6-acetylmorphine, S/P, Quant:
INTERPRETIVE INFORMATION: Opiates, Serum or Plasma,
Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 2 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. All drugs covered are the non-glucuronidated (free) form. The concentration value must be greater than or equal to the cutoff to be reported as positive. A very small amount of an unexpected drug analyte in the presence of a large amount of an expected drug analyte may reflect pharmaceutical impurity. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Amphetamine, S/P, Quant:
INTERPRETIVE INFORMATION: Amphetamines, Serum or Plasma, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 20 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Phencyclidine (PCP), S/P, Quant:
INTERPRETIVE INFORMATION: Phencyclidine (PCP), Serum or Plasma, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 10 ng/mL.

For medical purposes only; not valid for forensic use.

The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Diazepam, S/P, Quant:

INTERPRETIVE INFORMATION: Benzodiazepines, Serum or Plasma, Quantitative

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry.

Positive cutoff: 20 ng/mL unless specified below:

Diazepam	5 ng/mL
Alprazolam	5 ng/mL
Alpha-hydroxyalprazolam	5 ng/mL
Clonazepam	5 ng/mL
7-aminoclonazepam	5 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

08-Jun-20 11:40:00 Butalbital, S/P, Quant:
INTERPRETIVE INFORMATION: Barbiturates, Serum or Plasma, Quantitative

Methodology: Quantitative Gas Chromatography-Mass Spectrometry

Positive cutoff: 50 ng/mL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS